Market Overview
The global gamma-aminobutyric acid (GABA) receptor market size was worth US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Gamma-Aminobutyric acid (GABA) is an important inhibitory neurotransmitter found in the central nervous system of mammals. The neurotransmitter reduces the activity of neurons to which it binds, thus is used to control anxiety or fear when neurons are overexcited. GABA receptors are protein molecules that respond to neurotransmitter GABA.
Market Dynamics
The global gamma-aminobutyric acid (GABA) receptor market growth is driven by the rise in incidences of neurological disorders and increase in aging population, increased funding by government and private organizations across emerging economies for the treatment of neurological disorders is expected to provide growth opportunities for market growth.
Rise in incidences of neurological disorders coupled with the introduction of novel drugs are expected to drive the market growth
Increasing prevalence of epilepsy are the major driving factors of the market. For instance, According to World Health Organization (WHO) around 50 million people worldwide have epilepsy. The average incidence of epilepsy each year in the U. S is estimated at 150,000 or 48 for every 100,000 people. It was also found that in the United States, the number of males and females with Epilepsy was 1,477,323 and 1,331,276, respectively, in 2017. Benzodiazepines (BZDs) are important agents in the management of epilepsy. They are the first choice of drugs for status epilepticus and seizures associated with post-anoxic insult and are also frequently used to treat febrile, acute repetitive and alcohol withdrawal seizures. Clinical advantages of these drugs include they bind to the GABA-A receptor, increasing the calming effect, rapid onset of action, high efficacy rates and minimal toxicity. Benzodiazepines are used in various clinical situations because they have a broad spectrum of clinical activity and can be administered via several routes. For instance, In January 2020, the US FDA approved Neurelis, Inc drug Valtoco (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in people with epilepsy six years of age and older.
Side effects associated with the GABA receptor binding drugs is likely to hamper the market growth
The most common side effects of GABA include dizziness, anxiety, drowsiness, dry mouth, balance problems, constipation, blurred vision, itchiness, irritation, stomach pain, memory problems, increased appetite, joint and muscle pain.
COVID-19 Impact Analysis
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. This pandemic has disrupted growth in many economies across various domains. Management of anxiety, delirium, and agitation cannot be neglected in coronavirus disease (COVID-19). Antipsychotics are usually used for the pharmacological management of delirium, and confusion and behavioral disturbances. The concurrent use of treatments for COVID-19 and antipsychotics had eventual drug-drug interactions, which had a short-term negative impact on the market.
Segment Analysis
The diazepam segment is expected to hold the largest share in this market segment
Diazepam is likely to be the largest segment during the forecast period due to the new route of administration, strategic collaboration between companies for the development & commercialization of diazepam, and lower prescription cost for major diazepam factors attributed to the higher growth of the diazepam segment.
For instance, Valtoco a Neurelis, Inc product is a proprietary formulation of diazepam incorporating the unique combination of a vitamin E-based solution and Intravail absorption enhancement to obtain outstanding absorption, tolerability, and reliability in a nasal formulation and; it is delivered via a nasal formulation in a spray, being developed to manage children and adult patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity, also known as cluster seizures. The exact mechanism of action for diazepam is not fully understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor.
Geographical Analysis
North America region holds the largest market share of global gamma-aminobutyric acid (GABA) receptor market
North America is expected to dominate the global benzodiazepine drugs market due to more FDA approvals in that region. For instance, In February 2020, United States Food and Drug Administration provided approval to Merck for its Belsomra drug in the treatment of insomnia in patients with mild-to-moderate Alzheimer's disease. An article published by the National Center for Biotechnology Information, U.S. Library of Medicine in February 2018 stated that 50,000 to 150,000 people in the U.S. suffer from status epilepticus, with mortality estimated at less than 3% in children, but up to 30% in adults. For instance, Aquestive Therapeutics collaborated with Syneos Health, Covance, in 2020 completed Phase 3 trial of safety and tolerability study of chronic intermittent use of Diazepam Buccal Soluble Film (DBSF) in Pediatric, Adolescent and Adult Subjects with Epilepsy. An increase in the development of mental healthcare services and rising awareness towards anxiety disorders are responsible for the increase in the diagnosis of a generalized anxiety disorder (GAD).
Competitive Landscape
The global gamma-aminobutyric acid (GABA) receptor market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Merck Kagan, Bausch Health US LLC, Pfizer Inc, Lundbeck, Sanofi-Aventis U.S. LLC, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd, LGM PHARMA.
Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Key Companies to Watch
Pfizer Inc
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: XANAX (ALPRAZOLAM)- XANAX is a benzodiazepine indicated for the acute treatment of generalized anxiety disorder in adults.
Why Purchase the Report?
- Visualize the composition of the gamma-aminobutyric acid (GABA) receptor market segmentation by medications, type, indication and region highlighting the key commercial assets and players.
- Identify commercial opportunities in gamma-aminobutyric acid (GABA) receptor market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of gamma-aminobutyric acid (GABA) receptor market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players.
The global gamma-aminobutyric acid (GABA) receptor market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
Market Segmentation
Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Medications
Lorazepam (Ativan)
Midazolam (Versed)
Alprazolam (Xanax)
Diazepam (Valium)
Methohexital (Brevital)
Pentobarbital (Nembutal)
Amobarbital (Amytal)
Primidone (Mysoline)
- Vigabatrin
- Propofol
- Flumazenil
- Baclofen
- Gabapentin
- Zolpidem
- Others
Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Type
Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Indication
- Attention Deficit Hyperactivity Disorder
- Psychiatric Disorders
- Alzheimer's Disease
- General anesthesia
- Neuropathic pain
- Muscle relaxant
- Other
Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Region
- North America
- Europe
- Asia-Pacific
- Middle East & Africa
- South America
Table of Contents
1. Global Gamma-Aminobutyric Acid (GABA) Receptor Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Market Definition and Overview
3. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Executive Summary
- 3.1. Market Snippet by Type
- 3.2. Market Snippet by Medications
- 3.3. Market Snippet by Indication
- 3.4. Market Snippet by Region
4. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Market Dynamics
- 4.1. Market Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rise in incidences of neurological disorders coupled with the introduction of novel drugs
- 4.1.2. Restraints:
- 4.1.2.1. Side effects associated with the GABA receptor binding drugs
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
5. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Industry Analysis
- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pipeline Analysis
- 5.4. Pricing Analysis
- 5.5. Regulatory Analysis
6. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - COVID-19 Analysis
- 6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
7. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Medications
- 7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications Segment
- 7.1.2. Market Attractiveness Index, By medications Segment
- 7.2. Benzodiazepines*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
- 7.2.3. Lorazepam (Ativan)
- 7.2.4. Midazolam (Versed)
- 7.2.5. Alprazolam (Xanax)
- 7.2.6. Diazepam (Valium)
- 7.3. Barbiturates
- 7.3.1. Methohexital (Brevital)
- 7.3.2. Pentobarbital (Nembutal)
- 7.3.3. Amobarbital (Amytal)
- 7.3.4. Primidone (Mysoline)
- 7.4. Vigabatrin
- 7.5. Propofol
- 7.6. Flumazenil
- 7.7. Baclofen
- 7.8. Gabapentin
- 7.9. Zolpidem
- 7.10. Others
8. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Type
- 8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 8.1.2. Market Attractiveness Index, By Type
- 8.2. GABAA*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
- 8.3. GABAB
9. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Application
- 9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
- 9.2. Alzheimer's Disease*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
- 9.3. Attention Deficit Hyperactivity Disorder
- 9.4. Psychiatric Disorders
- 9.5. General anesthesia
- 9.6. Neuropathic pain
- 9.7. Muscle relaxant
- 9.8. Other
10. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications
- 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1. U.S.
- 10.2.6.2. Canada
- 10.2.6.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications
- 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.1. Germany
- 10.3.6.2. U.K.
- 10.3.6.3. France
- 10.3.6.4. Italy
- 10.3.6.5. Spain
- 10.3.6.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1. Brazil
- 10.4.6.2. Argentina
- 10.4.6.3. Rest of South America
- 10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.1. China
- 10.5.6.2. India
- 10.5.6.3. Japan
- 10.5.6.4. Australia
- 10.5.6.5. Rest of Asia Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Key Developments and Strategies
- 11.3. Company Share Analysis
- 11.4. Product Benchmarking
- 11.5. Key Companies to Watch
- 11.6. Company with disruptive technology
12. Global Gamma-Aminobutyric Acid (GABA) Receptor Market- Company Profiles
- 12.1. Pfizer Inc*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
- 12.2. Merck KGaA
- 12.3. Bausch Health US LLC
- 12.4. Lundbeck
- 12.5. Sanofi-Aventis U.S. LLC
- 12.6. Amneal Pharmaceuticals LLC
- 12.7. Sun Pharmaceutical Industries Ltd
- 12.8. LGM PHARMA
LIST NOT EXHAUSTIVE
13. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - DataM
- 13.1. Appendix
- 13.2. About Us and Services
- 13.3. Contact Us
